Peter Greenleaf

Peter Greenleaf is a declared insider at 4 companies (senior executive); the most frequent names are Aurinia Pharmaceuticals Inc., Pelthos Therapeutics Inc. and Biodelivery Sciences International Inc. The record holds 21 filings, for trades running from 11 May 2021 to 2 October 2026.

The open-market side counts 1 purchase for €18k alongside 7 sales for €975k. On balance, insiders were net sellers of €957k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 9 share grants and 2 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

On 6 October 2026 came the latest disclosure, an open-market sale for €15k in Pelthos Therapeutics Inc. The latest purchase dates back some time: it was published 1,985 days ago, on 12 May 2021. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.